Hematology Frontier

With the rapid advancements in medical technology and deeper insights into the mechanisms of lymphoma, traditional chemotherapy is gradually giving way to a new era of precision-targeted and immunotherapies. Innovative drugs are emerging like bamboo shoots after the rain, offering personalized treatment paths tailored to lymphoma patients. This marks the dawn of a new era in disease management, with the promise of more effective and optimistic treatment outcomes. At the 12th Lu Daopei Hematology Forum, Hematology Frontier invited Dr. Hongmei Jing from Peking University Third Hospital to provide a comprehensive analysis of the current state of lymphoma treatment in China, explore future research directions, and discuss the field's ongoing development.

The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year's conference, two studies conducted by Professor Xiaoyan Ke from Peking University Third Hospital/Beijing Chaoyang Hospital and Professor Kai Hu from Beijing Chaoyang Hospital were presented, highlighting how combined autologous hematopoietic stem cell transplantation and CAR-T cell therapy can improve survival rates for lymphoma and multiple myeloma patients.

Multiple Myeloma (MM) is a common hematologic malignancy, and with the emergence of immunotherapy, particularly CAR-T therapy as a revolutionary immunotherapeutic approach, the survival of patients with relapsed/refractory multiple myeloma (R/R MM) has significantly improved. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, United Kingdom, focusing on the latest advancements in stem cell transplantation and cell therapy, driving towards better clinical outcomes for hematologic disease patients. At this conference, Professor Chunrui Li from Tongji Hospital affiliated with Huazhong University of Science and Technology School of Medicine in China presented a study comparing the efficacy of five currently available BCMA-targeting CAR-T cell products, attracting widespread attention. In this exclusive interview, Professor Chunrui Li shares the main findings of the study and provides insightful interpretations of the latest research advancements in CAR-T cell therapy for R/R MM.

Graft failure is a rare but fatal complication following haploidentical allogeneic hematopoietic stem cell transplantation. A second transplant is almost the only salvage measure for transplant failure. However, outcomes from second transplants have generally been poor, as reported in previous literature. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was held in Glasgow, UK, from April 14th to 17th, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, driving better clinical outcomes for patients with blood disorders. At this conference, a team led by Professor Yuqian Sun from Peking University People's Hospital presented their findings in an oral report titled "Salvage Haploidentical Transplantation with Flu/Cy Regimen and Donor Switching After Primary Graft Failure: Follow-Up Results," which garnered significant attention. Professor Sun was invited to share the main results of this study and the progress in salvage treatments for graft failure after haploidentical allogeneic hematopoietic stem cell transplantation.

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. At this EHA conference, a study (S200) by Professors Juan Du and Jing Lu from Shanghai Changzheng Hospital was selected for an oral presentation. This study explored the efficacy and safety of GC012F in the first-line treatment of newly diagnosed high-risk multiple myeloma patients eligible for transplantation. To discuss the study and the treatment of multiple myeloma, "Oncology Frontier - Hematology Frontier" conducted an interview with Professor Jing Lu.

From June 13th to 16th, 2024, the 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, the capital of Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from all over the world each year to share and discuss innovative concepts and the latest scientific and clinical research achievements in hematology. At this year's EHA conference, several studies from Professor Xufan Zhu's team at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences were selected. This issue highlights two studies on pediatric bone marrow failure diseases (acquired aplastic anemia and Shwachman-Diamond syndrome) and includes insightful commentary from Professor Zhu.

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. At this EHA conference, a study (S200) by Professors Juan Du and Jing Lu from Shanghai Changzheng Hospital was selected for an oral presentation. This study explored the efficacy and safety of GC012F in the first-line treatment of newly diagnosed high-risk multiple myeloma patients eligible for transplantation. To discuss the study and the treatment of multiple myeloma, "Oncology Frontier - Hematology Frontier" conducted an interview with Professor Jing Lu.

The 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) Congress was held in Bangkok, Thailand, from June 22 to June 26, 2024. As the most influential international event in the field of thrombosis and haemostasis, the ISTH Congress attracts thousands of top experts and scholars from around the world each year, with its profound academic impact and rich academic content. "Oncology Frontier - Hematology Frontier" is dedicated to synchronously delivering cutting-edge academic information. Here, we highlight outstanding research findings to provide academic reference information for the field of hematological diseases.

From July 5th to 7th, the highly anticipated 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China were grandly held in Guangzhou. Based on the actual situation of cancer incidence in China, the conference specially invited authoritative experts in the field of oncology and carefully selected outstanding papers from the 2024 ASCO conference for comprehensive and in-depth interpretation. During the conference, "Oncology Frontier - Hematology Frontier" conducted an exclusive interview with Professor Tiejun Gong from the Harbin Institute of Hematology and Oncology. He shared his profound insights and unique academic perspectives on major studies presented at ASCO this year, the progress of the novel CD3 x CD19 IgG4 bispecific antibody CN201, and the overall status and future prospects of hematologic oncology treatment in China.

Aggressive lymphomas progress rapidly and are prone to relapse, with existing treatments still failing to achieve a satisfactory cure rate. Particularly for high-risk patient groups, the demand for precise and efficient treatments is more urgent. The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) was held in Houston, USA, from September 4th to 7th, 2024, attracting top experts in the field of hematologic malignancies from around the world to exchange the latest research findings and discuss new strategies for treatment. During the conference, "Hematology Frontier" had the honor to interview Dr. Astrid Pavlovsk from the Pavlovsky Center. She provided an in-depth analysis of the efficacy, safety, and current status of new therapies in the treatment of aggressive lymphomas, with a special focus on key issues such as patient individual differences, offering insights for clinical practice.